Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COR-1004 Single Ascending Dose Study in Healthy Volunteers with Elevated LDL Cholesterol
NCT07229118Phase 1Recruiting
- Start
- Nov 2025
- Primary completion
- Feb 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of COR-1004 in hyperlipidemia (16 cohorts). Primary endpoints: Occurrence of Clinical and Laboratory Adverse Events at 90 days and Severity of Clinical and Laboratory Adverse Events at 90 days. Started Nov 2025; status: recruiting.
02
Drugs
COR-1004
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT07229118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229118.